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Abstract
Background: Recently EBUS-TBNA, which has a sensitivity of 94.6%, specificity of 100% and diagnostic accuracy
rate of 96.3% as previously reported, has been widely used for patients with mediastinal and hilar
lymphadenopathy or suspected lung cancer to get accurate diagnosis. The purpose of the current study was to
evaluate the usefulness of EBUS-TBNA in obtaining cytological and histological diagnosis of mediastinal and hilar
lymph nodes compared to the results obtained with conventional mediastinoscopy as previously reported, and to
assess the relationship of diagnostic accuracy and number of passes and size of lymph nodes.
Methods: 101 patients with mediastinal and hilar lymphadenopathy or suspected lung cancer in our institution
were included in this prospective study. EBUS-TBNA was performed in all cases. The final diagnosis was confirmed
by cytology, surgical results, and/or clinical follow-up for at least 6 months. Sensitivity, specificity, accuracy, and
positive and negative predictive values were calculated using standard formulas.
Results: In 101 patients, EBUS-TBNA was successfully performed to obtain samples from 225 lymph nodes, 7 lung
masses, 1 mediastinal mass and 2 esophageal masses. 63 malignant tumors and 38 benign diseases were confirmed.
Epidermal growth factor receptor mutation was detected in 10 biopsy samples, and epidermal growth factor receptor
mutation was detected in 4 cases. With respect to the correct diagnosis of mediastinal and hilar lymphadenopathy,
EBUS-TBNA had a sensitivity of 95.08%, specificity of 100%, positive predictive value of 100%, negative predictive value
of 93.02%, and overall accuracy of 97.02%. The relationship of diagnostic accuracy and number of lymph node passes or
size of lymph nodes was both insignificant (p = 0.27; p = 0.23). The procedure was uneventful without complications.
Conclusions: EBUS-TBNA is an accurate and safe tool in diagnosis of mediastinal and hilar lymphadenopathy. It
cannot completely replace mediastinoscopy, it may indeed reduce the number of mediastinoscopy procedures. In
some cases, it can necessarily be the first-line procedure before mediastinoscopy.
Background
Patients with mediastinal lymphadenopathy or sus-
pected lung cancer required accurate diagnosis to
determine optimal treatment. For these patients, med-
iastinal nodal sampling is often necessary and has tra-
ditionally been performed by mediastinoscopy or
anterior mediastinotomy. However, mediastinoscopy,
with a sensitivity of 80% to 85% and a specificity of
nearly 100%, which is considered the gold standard for
diagnosis with tissue confirmation of mediastinal lym-
phadenophy and lung cancer with mediastinal or hilar
lymph nodes involved, does not allow access to all
lymph node stations and is associated with a rate of
morbidity that is not insignificant [1]. This situation
has led to the promotion in recent years of minimally
invasive techniques for mediastinal lymph node
evaluation.
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chial needle aspiration (EBUS-TBNA) is a new techni-
que that combines endoscopic visualization with high
frequency ultrasound imaging, which is used to obtain
cytological and histological samples of lesions adjacent
to the tracheobronchial tree [2-4]. This makes it easier
to locate the lymph nodes to be sampled. As Yasufuku
and colleagues [4] reported, EBUS-TBNA had a sensitiv-
ity of 94.6%, specificity of 100% and diagnostic accuracy
rate of 96.3%, which seemed to be superior to those of
mediastinoscopy. However, whether EBUS-TBNA can
be applied as the first-line procedure for diagnosis of
mediastinal lymphadenopathy is still controversial,
because of its false negative rate to some extent [5].
Moreover, there is few studies reported comparing the
relationship of diagnostic accuracy and number of
passes or size of lymph nodes. The main aim of our
study was to evaluate the role of EBUS-TBNA in obtain-
ing cytological and histological diagnosis of mediastinal
lymph nodes compared to the results obtained with
conventional mediastinoscopy as previously reported,
and to assess the relationship of diagnostic accuracy
with number of passes and size of lymph nodes.
Methods
Patients
Patients having mediastinal lymphadenopathy or with
mediastinal or hilar lesion suspected of lung cancer
detected on enhanced thoracic CT were included in this
prospective study. Between March to October 2009, 101
patients in our institution met this inclusion criteria and
were included in this study. The study was approved by
the ethical committee of Fudan University Shanghai
Cancer Center and a written informed consent was
obtained in all the patients.
EBUS-TBNA procedure
EBUS-TBNA was performed under venous anaesthesia.
Patients were monitored for electrocardiogram, pulse
oximetry, and blood pressure with the presence of an
anesthesiologist. A flexible bronchoscope containing an
ultrasound probe (XBF-UC206F-OL8; Olympus) was
inserted via the laryngeal mask and guided through the
trachea and the bronchial tree towards the appropriate
area of the mediastinum. The targeted lymph nodes or
masses were identified using bronchoscopic visualization
and ultrasound imaging. A needle (NA-201SX-4022;
Olympus) extended from the bronchoscope through the
bronchial wall was used to puncture the lesion and to
aspirate tissue. A lymph node or mass could be punctu-
red three to four times to gain an adequate sample, and
several lymph nodes could be punctured during the
same session. The aspirates were then smeared on slides
and simultaneously sent to pathology laboratory for
subsequent cytology. The cytology sample was consid-
ered adequate if it contained malignant cell or a large
number of lymphoid cells confirmed by the cytologist,
and then the operation is terminated. The lymph nodes
punctured were grouped according to the puncture site:
the upper paratracheal (2R, 2L), the subcarinal station
(7), the lower paratracheal and hilar station (4R, 4L,
10R, and 10L), the right paraesophageal (8R) and the
interlobar station (11L,11R).
Histological cores were collected and fixed with for-
malin and stained with hematoxylin and eosin for
further histology examination. In some cases, immuno-
histochemistry was performed for additional informa-
tion, and EGFR mutation was also evaluated.
Statistical analysis
The EBUS-TBNA diagnosis was confirmed by cytology,
surgical results, and/or clinical follow-up for at least 6
months. A positive cytological result of malignancy was
accepted as evidence, and the patients were treated
accordingly.
The data were entered into a database and analyzed
with the SPSS statistical software package (SPSS 15.0
Chicago, Illinois, USA). A descriptive analysis was car-
ried out in which categorical variables were expressed as
absolute and relative frequencies, and continuous vari-
ables as means (SD). The c2 was used to compare pro-
portions in independent groups. The spearman analysis
was used to compare correlation between two indepen-
dent groups. A P value of less than 0.05 was considered
significant. Sensitivity, specificity, accuracy, and positive
and negative predictive values were calculated using
standard formulas.
Results
Patient characteristics
We studied consecutively all the patients who under-
went EBUS-TBNA for the evaluation of mediastinal
and/or hilar lymph nodes and mediastinal/hilar lesion
on an inpatient basis between March to October 2009.
A total of 101 patients with a mean age of 57.4 years
(range, 24-84) were enrolled in this study, including 68
males and 33 females. Clinically, among these patients,
55 patients were suspected for lung cancer, 2 patients
were suspected for esophageal carcinoma, one patient
suffered from a malignant mediastinal mass and 43
benign mediastinal lymphadenopathy, who needed
pathological diagnosis (see Table 1). All patients were
followed up for at least 6 months.
Operation parameters
A total of 225 lymph nodes, 7 lung masses, 1 mediast-
inal mass and 2 esophageal masses were biopsied.
Details of lymph node stations and masses punctured
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nodes were punctured once, and 74 lymph nodes were
punctured more than once (range, 2-5) (see Table 4).
Diameter of lymph nodes ranged from 0.6 cm to 10.5
cm with a median diameter of 2.04 cm. There were 154
lymph nodes of which maximal diameter was <2 cm,
and 71 lymph nodes of which maximal diameter was >2
cm (see Table 5). Mean period of each TBNA passes
was 4.9 minutes and mean stay length in hospital was 2
days. Mediastinoscopy was conducted in 23 patients,
video-assisted thoracotomy surgery (VATS) was con-
ducted in 2 patients and 2 patients received transbron-
chial lung biopsy (TBLB) procedure. No procedure-
related complications such as pneumothorax, pneumo-
mediastinum or excessive bleeding ever occurred in this
study (see Table 2 &3).
Diagnostic yield
According to the cytological and histological results, 63
malignant tumors and 38 benign diseases were con-
firmed. Of these 63 patients, there were 24 cases of ade-
nocarcinoma, 5 cases of squamous carcinoma, 20 cases
of small cell lung cancers, 9 cases of undifferentiated
carcinoma, one case of renal carcinoma with mediastinal
lymph node metastasis and two cases of lymphoma.
There were 38 patients with benign diseases: 13 cases
with no malignancy evidences, 14 cases with granuloma-
tous inflammation, 4 cases with sarcoidosis, 4 cases with
tuberculosis, one small B cell tumor, one lymph node
hyperplasia and one chronic lymph node inflammation.
Meanwhile, EBUS-TBNA failed to reveal one small cell
lung cancer, one squamous carcinoma, one undifferen-
tiated carcinoma, which were finally diagnosed by
further confirmatory tests (see Table 6).
The sensitivity of real-time EBUS-TBNA was 95.08%
and specificity was 100%. Also, the positive predictive
v a l u ea n dt h en e g a t i v ep r e d i c t i v ev a l u ew a s1 0 0 %a n d
93.02%, respectively. The overall accuracy was 97.02%
(see Table 2). The relationships of diagnostic accuracy
with number of lymph node passes and with size of
lymph nodes were both insignificant (p = 0.27; p = 0.23)
(see Table 4&5).
EGFR mutation measurement
EGFR mutation was detected in 10 EBUS-TBNA biopsy
samples which were confirmed adenocarcinoma on
cytological level. In 4 cases, EGFR mutation (40%) was
confirmed. One was heterozygosity deletion (E752-
E759del) of exon 19, one was heterozygosity deletion
(E746-E750del) of exon 19, and two were point muta-
tions (L858R) of exon 21. No EGFR mutation was found
in the other six patients (see Table 7).
Discussion
For many years surgical biopsy - principally mediastino-
scopy - has been regarded as the “standard procedure”
for sampling mediastinal lymph nodes [1]. However,
mediastinoscopy can only sample nodal stations 1-4, 7,
access to hilar nodal stations could be difficult and may
require thoracoscopy and on occasion a thoracotomy.
Moreover, it cannot be repeatedly operated on the same
patient [5,6]. Contrarily, EBUS-TBNA, when combined
with EUS, can sample all the key nodal stations and also
can be performed repeatedly [7,8]. In our study, 225
lymph nodes were biopsied and 10 stations of mediast-
inal and hilar nodes were punctured (see Table 2 &3).
Moreover, nearly every lymph nodal group had been
Table 1 Patient characteristics and pre-operation
diagnosis
Patient characteristics
Patients N = 101
Male/female gender 68/33
Median age(year)(range) 57.4 years (24-84)
Pre-operation diagnosis
Suspected for lung cancer N = 55
Suspected for esophageal carcinoma N = 2
Malignant mediastinal mass N = 1
Mediastinal and hilar lymphadenopathy N = 43
Pre-operation diagnosis: mainly based on CT feature.
Table 2 Operation parameters, further confirmation
modalities, lymph node size and diagnostic yield
Operation parameters
Number of lymph nodes biopsied N = 225
Number of lung mass biopsied N = 7
Number of esophageal masses biopsied N = 2
Number of mediastinal masses biopsied N = 1
Mean period of each TBNA pass (min) 4.9
Mean stay length in hospital (day) 2.0
Complications No case
Further confirmation modalities
Mediastinoscopy N = 23
VATS N = 2
TBLB N = 2
6-months follow-up N = 74
Lymph node size (mm)
Long axis 20.4 (6-105)
Short axis 17 (6-50)
Diagnostic yield %
Sensitivity 95.08
Specificity 100
Accuracy 97.02
Positive predictive value (PPV) 100
Negative predictive value (NPV) 93.02
VATS: video-assisted thoracotomy surgery; TBLB: transbronchial lung biopsy.
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four lymph node stations. A total number of 305 TBNA
passes of lymph nodes were conducted (see Table 3).
On the other hand, mediastinoscopy is more invasive
than endoscopic techniques and results in a neck scar
which may be cosmetically unacceptable to some
patients. Unfortunately it does have a 2% risk of mor-
bidity and 0.08% mortality [1,9,10]. In this study, 101
patients received EBUS-TBNA, of which mediastino-
scopy was conducted in 23 patients, 2 patients received
VATS and 2 patients received TBLB procedure, no pro-
cedure-related complications ever occurred (see Table
2). The mean period of each EBUS-TBNA was 4.9 min-
utes and mean stay length in hospital was 2 days, which
seemed to be more minimal invasive, compared with
those parameters of mediastinoscopy.
Furthermore, though viewed as the gold standard for
mediastinal nodal assessment, the diagnostic sensitivity
of cervical mediastinoscopy is only 78-81%, which is
inferior to that of EBUS-TBNA, as reported in two
recent systematic reviews [1,11]. Mediastinoscopy has a
negative predictive value of 91% which is also inferior to
that of endoscopic techniques thus far [1,11]. Similarly
found in previous studies [12,13], the sensitivity of real-
time EBUS-TBNA in our study was 95.08% and the
negative predictive value was 93.02% (see Table 8). This
diagnostic yield was obviously in favor of EBUS-TBNA
over cervical mediastinoscopy. However, current data
was not consistent. Another study of 33 patients evalu-
ating EBUS versus cervical mediastinoscopy for nodal
staging of patients with suspected or confirmed lung
cancer revealed a lower sensitivity and slightly inferior
negative predictive value for EBUS with similar accura-
cies (90.9 versus 93.9% for EBUS and cervical mediasti-
noscopy, respectively). In the study, the prevalence of
N2 or N3 disease was lower at 39.4%. Importantly, three
patients were upstaged by cervical mediastinoscopy
from N0 (on EBUS) to N2, indicating it may not com-
pletely replace cervical mediastinoscopy [14]. According
to our study, 46 patients with suspected or confirmed
lung cancer received EBUS-TBNA, 2 patients with con-
firmed lung cancer for restaging after chemotherapy,
and confirmatory EBUS-TBNA was operated on 43
patients with preoperatively suspected mediastinal dis-
eases. Besides, 7 lung masses, 1 mediastinal mass and 2
esophageal masses were biopsied by EBUS-TBNA.
Regarding the final cytological and histological results
showed above, EBUS-TBNA successfully diagnosed 58
malignant tumors and failed to reveal one small cell
lung cancer, one squamous carcinoma, one undifferen-
tiated carcinoma, which were finally diagnosed by
further confirmatory tests (see Table 9). The malignancy
prevalence was 60.4% in our study. Compared with
those different results, in our study, it was suggested
that the variability in performance may relate to the sig-
nificant variation in disease prevalence. When disease
prevalence was high, existing data favored EBUS but
when it was moderate then cervical mediastinoscopy
appeared superior. (See Table 10)
Another unsettled point is that whether EBUS-TBNA
can replace mediastinoscopy as first-line procedure for
diagnosis benign mediastinal diseases such as sarcoido-
sis, tuberculosis, etc. As Nakajima and colleagues
Table 3 Location of Lymph Node Station Biopsied by EBUS-TBNA and number of TBNA passes of each Lymph Node
Station
Right upper paratracheal (2R) N = 42 Left upper paratracheal (2L) N = 1
Right lower paratracheal (4R) N = 110 Left lower paratracheal (4L) N = 41
Subcarina (7) N = 80 Right paraesophageal (8R) N = 2
Right hilar (10R) N = 16 Left hilar (10L) N = 7
Right interlobar (11R) N = 4 Left intherlobar (11L) N = 2
Total N = 305
EBUS-TBNA: endobronchial ultrasound guided transbronchial needle aspiration.
Table 4 The relationship of diagnostic accuracy and
number of lymph node passes
Number of lymph node passes
N=1 N>1
Total (N = 225) 151 74
Successful passes 117 61
Unsuccessful passes 34 13
Diagnostic accuracy 77.5% 82.4%
P = 0.27
N > 1 including N = 2-5.
Table 5 The relationship of diagnostic accuracy and size
of lymph nodes
Maximal diameter of lymph nodes
≦2c m > 2c m
Total (N = 225) 154 71
Successful passes 119 60
Unsuccessful passes 35 11
Diagnostic accuracy 77.3% 84.5%
P = 0.23
The spearman correlation analysis was used to compare correlation between
the two groups.
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conventional diagnostic modalities for patients with sus-
picious stage I sarcoidosis on chest roentgenogram. In
their study, they compared EBUS-TBNA with TBLB and
BAL and got their conclusion, but they did not compare
with mediastinoscopy. In ourr e s e a r c h ,3 8b e n i g nd i s -
eases were diagnosed. And 5 cases of granulomous
inflammation were diagnosed by EBUS-TBNA. Also, of
4 patients with tuberculosis, one case was diagnosis by
EBUS-TBNA. Since non-caseating granuloma can be
detected by EBUS-TBNA, sarcoidosis and tuberculosis
can be diagnosed with the combination of clinical fea-
tures and laboratory evidences.
Since there are few studies analyzing the relationship
between diagnostic accuracy and number of lymph node
passes or size of lymph nodes reported previously, we
assessed the correlation of diagnostic accuracy and the
two parameters above. Though the diagnostic accuracy
of EBUS-TBNA should be higher when the lymph node
s i z ew a sl a r g e ro rn u m b e ro fp a s s e sw a sm o r eo nt h e
theoretical basis, we found that the relationship of diag-
nostic accuracy and number of passes was insignificant
(see Table 4 &5). Similarly, there was no significant cor-
relation between diagnostic accuracy and size of lymph
nodes. Our results suggest that neither number of
lymph node passes nor size of lymph nodes be the key
factor which determines the success of EBUS-TBNA.
The certainty that the needle is punctured into the
lymph node and enough samples are collected during
EBUS-TBNA procedure is much more important.
Another potential advantage of EBUS-TBNA is that
the cytological samples can provide molecular biological
information that will possibly be useful for the treat-
ment of advanced lung cancer. In our study, we detected
EGFR mutation in ten biopsy samples. We found 4
EFGR mutation cases: one heterozygosity deletion
(E752-E759del) of exon 19, one heterozygosity deletion
(E746-E750del), and two point mutations (L858R) of
exon 21. We detected EGFR mutation on the cytological
level, which was different from what Nakajima reported
on the histological level in 2007 [16]. Though whether
EGFR mutation found in metastatic lymph nodes is
accordance with that of the primary tumor is still
unknown, however, molecular biological information
provided by EBUS-TBNA is evidently of great value and
maybe it can guide targeted therapy for advanced lung
cancer patients. Obviously more researches are needed
for further confirmation.
Conclusions
EBUS-TBNA was an accurate and safe tool in diagnosis
of mediastinal lymphadenopathy and lung cancer. Surely
EBUS-TBNA cannot completely replace mediastino-
scopy so far, it may indeed reduce the number of med-
iastinoscopy procedures. In patients with positive lymph
nodes suspected by enhanced thoracic CT and PET/CT,
it can necessarily be the first-line procedure before
mediastinoscopy.
Table 6 Final cytological and histological results
Malignancy (N = 61)
Adenocarcinoma N = 24
Small cell lung cancer N = 20
Squamous carcinoma N = 5
Undifferentiated carcinoma N = 9
Renal carcinoma metastasis N = 1
Benign diseases (N = 40)
No MT evidence N = 13
Granulomatous inflammation N = 14
Sarcoidosis N = 4
Tuberculosis N = 4
Lymphoma N = 2
Small B cell tumor N = 1
Lymph node hyperplasia N = 1
Chronic inflammation N = 1
Table 7 Results of EGFR mutation detection on the
cytological level
EGFR mutation status Number
Heterozygosity Deletion (E752-E759del) of Exon 19 1
Heterozygosity Deletion (E746-E750del) of Exon 19 1
Point Mutations (L858R) of Exon 21 2
Negative 6
Table 8 Diagnostic Ability of Endobronchial Ultrasound
Guided Transbronchial Needle Aspiration: Comparison
With Previous Studies
%
Author Year N Sensitivity Specificity PPV NPV Accuracy
Yasufuku
[4]
2005 108 94.6 100 100 89.5 96.3
Vincent
[12]
2008 152 95 100 100 97 98.7
Andrade
[13]
2008 46 96.4 100 100 92.5 97.8
Our study 2009 101 95.08 100 100 93.02 97.02
PPV: positive predictive value; NPV: negative predictive value.
Table 9 Comparison of real-time EBUS-guided TBNA
results with final diagnosis of all patients
EBUS-TBNA results
Final diagnosis malignant benign Total
Malignant 58 3 61
Benign 0 40 40
Total 58 43 101
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Table 10 Comparative diagnostic performance of EBUS-TBNA and mediastinoscopy
Technique Nodes Risks Sensitivity NPV Prevalence
Mediastinoscopy
[1]
1-4, 7 0.08% mortality and 2% morbidity: arrhythmias [15], haemorrhage, thoracic duct
injury, recurrent laryngeal nerve injury, pneumonia, bronchial/pleural laceration [1]
78-81% 91% 39%
EBUS-TBNA 2-4, 7,
10-12
None 95.08% 93.02% 60.4%
EBUS-TBNA: based on data from our study; Mediastinoscopy: based on data from previous studies.
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